DUN09716

Cas：300809-71-6

Product Information：

DUN09716 is KRAS inhibitor with potential antitumor activity. DUN09716 was reported inn patent US 9884046. DUN09716 has CAS# 300809-71-6, no formal name. For the convenience of scientific communication, we named it as DUN09716 (combined from Inchi key plus CAS#) according to Hodoodo Chemical Nomenclature

Chemical Formula: C13H9ClN2S2

Exact Mass: 291.9896

Molecular Weight: 292.799

Elemental Analysis: C, 53.33; H, 3.10; Cl, 12.11; N, 9.57; S, 21.90

Synonym:

DUN-09716

DUN 09716

Chemical Name:

4-[(Benzo[d]thiazol-2-yl)thio]-3-chloroaniline

InChi Key: 

DTSNLMOLTVGCGZ-UHFFFAOYSA-N

InChi Code: 

InChI=1S/C13H9ClN2S2/c14-9-7-8(15)5-6-11(9)17-13-16-10-3-1-2-4-12(10)18-13/h1-7H,15H2

Smiles Code:

NC1=CC=C(SC2=NC3=CC=CC=C3S2)C(Cl)=C1

Technical Data：

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

In Vitro:

KRAS inhibitor-9 bound to KRASG12D, KRAS G12C and KRAS Q61H protein with a moderate binding affinity of -5.38, -5.41, and -3.97 kcal/mol, respectively.

KRAS inhibitor-9 (0-100 μM) shows strong inhibition selectivity in NSCLC cells with IC50s ranging from 39.56 to 66.02 μM for H2122, H358 and H460 cells (at 72 hours).

KRAS inhibitor-9 (0-100 μM; 24 hours) blocks GTP-KRAS formation in H2122, H358 and H460 cells.

KRAS inhibitor-9 (25-100 μM; 48 hours) inhibits the activation of KRAS downstream signaling pathway.

KRAS inhibitor-9 (0-100 μM; 24-72 hours) induces cell cycle arrest and apoptosis in NSCLC.

References：

1. Xie C, et al. Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells. Front Pharmacol. 2017;8:823. Published 2017 Nov 14.

Products are for research use only. Not for human use.